BioPharmSignal logoBioPharmSignal

Biotech News

Xenon to Report Q1 2026 Financial Results on May 7, 2026

Xenon (XENE)XenonEarnings

VANCOUVER, British Columbia and BOSTON, MA, April 30, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need,

Related news

XENEXenon2026-07-30 20:01 EST

Xenon to Report Q2 2026 Financial Results on August 6, 2026

XENEXenon2026-08-06 20:01 EST

Xenon Reports Q2 2026 Financial Results and Provides Business Update

ABOSAcumen Pharmaceuticals2026-08-05 20:00 EST

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

PRAXPraxis Precision Medicines2026-07-30 20:01 EST

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

TNXPTonix Pharmaceuticals2026-07-27 11:00 EST

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026

XERSXeris Pharmaceuticals2026-07-23 11:30 EST

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

HRMYHarmony Biosciences2026-07-21 12:05 EST

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

AXSMAxsome2026-07-14 11:00 EST

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

ADXNAddex Therapeutics2026-06-22 05:00 EST

Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026

View all latest news

Xenon

Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....

Recent company news

XENEXenon2026-08-06 20:01 EST

Xenon Reports Q2 2026 Financial Results and Provides Business Update

XENEXenon2026-07-31 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-07-30 20:01 EST

Xenon to Report Q2 2026 Financial Results on August 6, 2026

XENEXenon2026-07-02 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-05-29 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
64.55 USD
Market cap
5.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States